Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

(Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing ...

The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug ...

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...